Treating Individuals 3: From subgroups to individuals: General principles and the example of carotid endarterectomy

Lancet

Volumn 365, Issue 9455, 2005, Pages 256-265

  Rothwell, Peter M ^a,c   Mehta, Ziyah ^a   Howard, Sally C ^a   Gutnikov, Sergei A ^a   Warlow, Charles P ^b  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b WESTERN GENERAL HOSPITAL   (United Kingdom)

^c RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CAROTID ARTERY OBSTRUCTION; CAROTID ENDARTERECTOMY; CONTROLLED STUDY; DATA ANALYSIS; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOMES RESEARCH; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK REDUCTION; STATISTICAL MODEL; STATISTICAL SIGNIFICANCE; TREATMENT INDICATION;

EID: 12344278985     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)17746-0     Document Type: Review

References (67)

1. Asher R. Apriority: thoughts on treatment. Lancet. 2:1961;1403-1404
2. Rothwell PM. Subgroup analysis in randomised controlled trials: importance, indications and interpretation. Lancet. 365:2005;176-186
3. Haq IU, Jackson PR, Yeo WW, Ramsay LE. Sheffield risk and treatment table for cholesterol lowering for primary prevention of coronary heart disease. Lancet. 346:1995;1467-1471
4. Filippini G, Munari L, Incorvaia B, et al. Interferons in relapsing remitting multiple sclerosis: a systematic review. Lancet. 361:2003;545-552
5. Morris PJ, Johnson RJ, Fuggle SV, et al. Analysis of factors that affect outcome of primary cadaveric renal transplantation in the UK. Lancet. 354:1999;1147-1152
6. Rothwell PM, Warlow CP, on behalf of the European Carotid Surgery Trialists' Collaborative Group Prediction of benefit from carotid endarterectomy in individual patients: a risk modeling study. Lancet 1999; 353: 2105-10.
7. Rothwell PM, Eliasziw M, Gutnikov SA, et al. Pooled analysis of individual patient data from randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet. 361:2003;107-116
8. Ebrahim S, Davey Smith G. The 'number needed to treat': does it help clinical decision making? J Hum Hypertens. 13:1999;721-724
9. Furukawa TA, Guyatt CH, Griffith LE. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses. Int J Epidemiol. 31:2002;72-76
10. Dahlof B, Lindholm LH, Hansson L, Schersten B, Ekbom T, Wester PO. Morbidity and mortality in the Swedish trial in old patients with hypertension (STOP-hypertension). Lancet. 338:1991;1281-1285
11. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. BMJ. 291:1985;97-104
12. Rothwell PM, Eliasziw M, Gutnikov SA, et al, for the Carotid Endarterectomy Trialists' Collaboration. Effect of endarterectomy for recently symptomatic carotid stenosis in relation to clinical subgroups and the timing of surgery. Lancet 2004; 363: 915-24.
13. Hampton JR. Size isn't everything. Stat Med. 21:2002;2807-2814
14. Stiller CA. Centralised treatment, entry to trials and survival. Br J Cancer. 70:1994;352-362
15. Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine in acute myocardial infarction: the TRENT study. BMJ. 293:1986;1204-1208
16. Woods KL, Ketley D. Intravenous beta blockade in acute myocardial infarction. Doubt exists about external validity of trials of intravenous beta-blockade. BMJ. 318:1999;328-329
17. Rothwell PM. External validity of randomised controlled trials: 'To whom do the results of this trial apply? Lancet. 365:2005;82-93
18. Hill AB. The clinical trial. N Engl J Med. 247:1952;113-119
19. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors. Circulation. 102:2000;1893-1900
20. Schulz UGR, Rothwell PM. Sex differences in the angiographic and gross pathological appearance of carotid atherosclerotic plaques. J Neurol Sci. 187:(suppl 1):2001;S127
21. Sackett DL, Straus SE. Finding and applying evidence during clinical rounds: the "evidence cart" JAMA. 280:1998;1336-1338
22. Sackett DL. Applying overviews and meta-analyses at the bedside. J Clin Epidemiol. 48:1995;61-70
23. Ellis J, Mulligan I, Rowe J, Sackett DL. Inpatient general medicine is evidence based. Lancet. 346:1995;407-410
24. Laupacis A, Boysen G, Connolly S, et al. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomised controlled trials. Arch Intern Med. 154:1994;1449-1457
25. Yusuf S, Zucker D, Peduzzi P, et al. Effect of coronary artery bypass graft surgery on survival: overview of 10-year results from randomised trials by the Coronary Artery Bypass Graft Surgery Trialists' Collaboration. Lancet. 344:1994;563-570
26. Li W, Gueyffier F, Boissel JP, Girard P, Boutitie F, Cucherat M. Identification and prediction of responders to a therapy. A model and its preliminary application to hypertension. Arch Mal Coeur Vaiss. 91:1998;1059-1063. [In French]
27. Sanmuganathan PS, Ghahramani P, Jackson PR, Wallis EJ, Ramsay LE. Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart. 85:2001;265-271
28. West of Scotland Coronary Prevention Group. West of Scotland Coronary Prevention Study: identification of high-risk groups and comparison with other cardiovascular intervention trials. Lancet. 348:1996;1339-1342
29. Bundaj A, Yusuf S, Mehta SR, et al. Benefit of clopidogrel in patients with acute coronary syndromes without ST-segment elevation in various risk groups. Circulation. 106:2002;1622-1626
30. Antman EM, Cohen M, Bernink PJLM, et al. The TIMI risk score for unstable angina/non-ST elevation MI. A method for prognostication and therapeutic decision making. JAMA. 284:2000;835-842
31. Cohen M, Demers C, Garfinkel EP, et al. A comparison of low molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N Engl J Med. 337:1997;447-452
32. Pagliaro L, D'Amico G, Soronson TI, et al. Prevention of bleeding in cirrhosis. Ann Intern Med. 117:1992;59-70
33. International Study of Unruptured Intracranial Aneurysms Investigators. Unruptured intracranial aneurysms-risks of rupture and risks of surgical intervention. N Engl J Med. 339:1998;1725-1733
34. Boissel JP, Collet JP, Lievre M, Girard P. An effect model for the assessment of drug benefit: example of antiarrhythmic drugs in postmyocardial infarction patients. J Cardiovasc Pharmacol. 22:1993;356-363
35. Grover SA, Lowensteyn I, Esrey KL, Steinert Y, Joseph L, Abrahamowicz M. Do doctors accurately assess coronary risk in their patients? Preliminary results of the coronary health assessment study. BMJ. 310:1995;975-978
36. Rothwell PM. Incidence, risk factors and prognosis of stroke and transient ischaemic attack: the need for high-quality large-scale epidemiological studies. Cerebrovasc Dis. 16:(suppl 3):2003;2-10
37. Rothwell PM. Can overall results of clinical trials be applied to all patients? Lancet. 345:1995;1616-1619
38. Braitman LE, Davidoff F. Predicting clinical states in individual patients. Ann Intern Med. 125:1996;406-412
39. Nanchahal K, Duncan JR, Durrington PN, Jackson RT. Analysis of predicted coronary heart disease risk in England based on Framingham study risk appraisal models published in 1991 and 2000. BMJ. 325:2002;194-195
40. Hankey GJ, Slattery JM, Warlow CP. Transient ischaemic attacks: which patients are at high (and low) risks of serious vascular events? J Neurol Neurosurg Psychiatry. 55:1992;640-652
41. Rothwell PM, Slattery J, Warlow CP. A systematic review of clinical and angiographic predictors of stroke and death due to carotid endarterectomy. BMJ. 315:1997;1571-1577
42. Pearce LA, Hart RG, Halpern JL. Assessment of three schemes for stratifying stroke risk in patients with non-valvular atrial fibrillation. Am J Med. 109:2000;45-51
43. Kernan WN, Viscoli CM, Brass LM, et al. The Stroke Prognosis Instrument II (SPI II): a clinical prediction instrument for patients with transient ischaemia and non-disabling ischaemic stroke. Stroke. 31:2000;456-462
44. Lauer MS. Aspirin for primary prevention of coronary events. N Engl J Med. 346:2002;1468-1474
45. Baker S, Priest P, Jackson R. Using thresholds based on risk of cardiovascular disease to target treatment for hypertension: modelling events averted and number treated. BMJ. 320:2000;680-685
46. Isles CG, Ritchie LD, Murchie P, Norrie J. Risk assessment in primary prevention of coronary heart disease: randomised comparison of three scoring methods. BMJ. 320:2000;690-691
47. Montgomery AA, Fahey T, Peters TJ, MacIntosh C, Sharp DJ. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. BMJ. 320:2000;686-690
48. Robson J, Boomla K, Hart B, Feder G. Estimating cardiovascular risk for primary prevention: outstanding questions for primary care. BMJ. 320:2000;702-704
49. Ionnidis JPA, Lau J. The impact of high-risk patients on the results of clinical trials. J Clin Epidemiol. 50:1997;1089-1098
50. Nadeau SE. The use of expected value as an aid to decisions regarding anticoagulation in patients with atrial fibrillation. Stroke. 24:1993;2128-2134
51. Elwyn G, Edwards A, Eccles M, Rovner D. Decision analysis in patient care. Lancet. 358:2001;571-574
52. Thomson R, Parkin D, Eccles M, Sudlow M, Robinson A. Decision analysis and guidelines for anticoagulant therapy to prevent stroke in patients with atrial fibrillation. Lancet. 355:2000;956-962
53. No authors listed: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation Analysis of pooled data from five randomised controlled trials. Arch Intern Med 1994; 154: 1449-57.
54. Rothwell PM, Gutnikov SA, Warlow CP, et al. Re-analysis of the final results of the European Carotid Surgery Trial. Stroke. 34:2003;514-523
55. Bond R, Rerkasem K, Rothwell PM. A systematic review of the risks of carotid endarterectomy in relation to age and sex. Cerebrovasc Dis (in press).
56. Bond R, Rerkasem K, Rothwell PM. A systematic review of the risks of carotid endarterectomy in relation to the clinical indication and the timing of surgery. Stroke. 34:2003;2290-2301
57. Pocock SJ, McCormack V, Gueyffier F, Boutitie F, Fagard JP, Boissel JP. A score for predicting risk of death from cardiovascular disease in adults with raised blood pressure, based on individual patient data from randomised controlled trials. BMJ. 323:2001;75-81
58. Leteurtre S, Martinot A, Duhamel A, et al. Validation of the paediatric logistic organ dysfunction (PELOD) score: prospective, observational, multicentre study. Lancet. 362:2003;192-197
59. Jackson R. Updated New Zealand cardiovascular disease risk-benefit prediction guide. BMJ. 320:2000;709-710
60. Ramsay LE, Haq IU, Jackson PR, Yeo WW, Pickin DM, Payne JN. Targeting lipid-lowering drug therapy for primary prevention of coronary disease: an updated Sheffield table. Lancet. 348:1996;387-388
61. Kanis JA. Diagnosis of osteoporosis and assessment of fracture risk. Lancet. 359:2002;1929-1936
62. Altman DG, Royston P. What do we mean by validating a prognostic model? Stat Med. 19:2000;453-473
63. Rathore SS, Weinfurt KP, Gross CP, Krumholz HM. Validity of a simple ST-elevation acute myocardial infarction risk index: are randomised trial prognostic estimates generalizable to elderly patients? Circulation. 107:2003;811-816
64. Rose G. Strategy of prevention: lessons from cardiovascular disease. BMJ. 282:1981;1847-1851
65. Rose G. Sick individuals and sick populations. Int J Epidemiol. 14:1985;32-38
66. Bond R, Rerkasem K, Shearman CP, Rothwell PM. Time trends in the published risks of stroke and death due to endarterectomy for symptomatic carotid stenosis. Cerebrovasc Dis. 18:2004;37-46
67. Kastrup A, Groschel K, Krapf H, Brehm BR, Dichgans J, Schulz JB. Early outcome of carotid angioplasty and stenting with and without cerebral protection devices: a systematic review of the literature. Stroke. 34:2003;813-819